- Home
- DAVA vs AKBA Comparison
DAVA vs AKBA Comparison
Compare DAVA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- AKBA
- Stock Information
- Founded
- DAVA 2000
- AKBA 2007
- Country
- DAVA United Kingdom
- AKBA United States
- Employees
- DAVA N/A
- AKBA N/A
- Industry
- DAVA EDP Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- DAVA Technology
- AKBA Health Care
- Exchange
- DAVA Nasdaq
- AKBA Nasdaq
- Market Cap
- DAVA 885.9M
- AKBA 958.6M
- IPO Year
- DAVA 2018
- AKBA 2014
- Fundamental
- Price
- DAVA $13.79
- AKBA $3.74
- Analyst Decision
- DAVA Buy
- AKBA Strong Buy
- Analyst Count
- DAVA 9
- AKBA 5
- Target Price
- DAVA $25.33
- AKBA $6.90
- AVG Volume (30 Days)
- DAVA 639.0K
- AKBA 3.3M
- Earning Date
- DAVA 09-18-2025
- AKBA 08-07-2025
- Dividend Yield
- DAVA N/A
- AKBA N/A
- EPS Growth
- DAVA N/A
- AKBA N/A
- EPS
- DAVA 0.40
- AKBA N/A
- Revenue
- DAVA $1,007,631,882.00
- AKBA $184,909,000.00
- Revenue This Year
- DAVA $6.32
- AKBA $26.88
- Revenue Next Year
- DAVA N/A
- AKBA $44.34
- P/E Ratio
- DAVA $36.88
- AKBA N/A
- Revenue Growth
- DAVA 5.95
- AKBA N/A
- 52 Week Low
- DAVA $13.12
- AKBA $1.07
- 52 Week High
- DAVA $34.94
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- DAVA 45.78
- AKBA 45.31
- Support Level
- DAVA $13.98
- AKBA $3.47
- Resistance Level
- DAVA $15.20
- AKBA $3.64
- Average True Range (ATR)
- DAVA 0.55
- AKBA 0.16
- MACD
- DAVA 0.10
- AKBA -0.06
- Stochastic Oscillator
- DAVA 49.52
- AKBA 18.92
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.